Skip to main content
. Author manuscript; available in PMC: 2014 Feb 11.
Published in final edited form as: Cancer Cell. 2013 Jan 24;23(2):143–158. doi: 10.1016/j.ccr.2012.12.008

Figure 3. Phenformin treatment robustly activates AMPK pathway in K-Ras driven lung tumors in vivo.

Figure 3

(A) Lung tissue lysates from wild type FVB mice following i.p. injection of saline (0.9%), metformin (300 mg/kg) or phenformin (150 mg/kg) and immunoblotted with the indicated antibodies.

(B) Lysates of lung tumor nodules from Kluc, KLluc and KPluc mice treated with vehicle (water) or phenformin via 5 days ad lib feeding were immunoblotted with the indicated antibodies.

(C) Representative images of hematoxylin and eosin (H&E), P-AMPK or P-4E-BP1 stained Kluc, KLluc and KPluc lung tumor sections. P-AMPK or P-4E-BP1 positively stained cells (in green) and nuclei (in blue). Scale bar = 100 μm.

(D, E) Box plots representing the mean P-AMPK (D) or P-4E-BP1 (E) signal from Kluc, KLluc and KPluc lung tumors treated with vehicle or phenformin. n=6 mice analyzed per treatment group in each genotype (Kluc, KLluc and KPluc) treatment group. All data are represented as the mean ± SEM.